Foscarnet for chronic hepatitis B

[1]  O. Weiland,et al.  Treatment of chronic replicative hepatitis B virus infection with short-term continuous infusion of foscarnet , 1994, Infection.

[2]  A. Vegnente,et al.  Chronicity rate of hepatitis B virus infection in the families of 60 hepatitis B surface antigen positive chronic carrier children: Role of horizontal transmission , 1992, European Journal of Pediatrics.

[3]  K. Meyer zum Büschenfelde,et al.  Inhibition of hepatitis B virus specific DNA polymerase by intercalating agents , 1980, Medical Microbiology and Immunology.

[4]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.

[5]  Christian Gluud,et al.  Reported Methodologic Quality and Discrepancies between Large and Small Randomized Trials in Meta-Analyses , 2001, Annals of Internal Medicine.

[6]  Douglas G Altman,et al.  Systematic reviews in health care: Assessing the quality of controlled clinical trials. , 2001, BMJ.

[7]  V. Thakur,et al.  Transfusion‐Associated Hepatitis in a Tertiary Referral Hospital in India , 1999, Vox sanguinis.

[8]  A. M. Ferreira,et al.  Prevalência de marcadores sorológicos do vírus da hepatite B em trabalhadores do serviço hospitalar , 1999 .

[9]  J. V. Fernandes,et al.  [Prevalence of serologic markers of hepatitis B virus in hospital personnel]. , 1999, Revista de saude publica.

[10]  L. Simonsen,et al.  Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. , 1999, Bulletin of the World Health Organization.

[11]  B. Hirschel,et al.  Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995 , 1998, AIDS.

[12]  D. Cook,et al.  Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? , 1998, The Lancet.

[13]  K. Chayama,et al.  Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. , 1998, Journal of hepatology.

[14]  W. M. Lee,et al.  Hepatitis B virus infection. , 1997, The New England journal of medicine.

[15]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[16]  Á. Atallah,et al.  Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature Database (LILACS). , 1997, Sao Paulo medical journal = Revista paulista de medicina.

[17]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[18]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.

[19]  J. Hoofnagle,et al.  Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.

[20]  H. Thomas,et al.  Genetic variation in hepatitis B virus. , 1992, Gastroenterology.

[21]  S. Della Bella,et al.  Epidemiology of viral hepatitis in dialysis centers: a national survey. , 1992, Nephron.

[22]  H. Margolis,et al.  Hepatitis B: Evolving Epidemiology and Implications for Control , 1991, Seminars in liver disease.

[23]  D. Heymann,et al.  Transmission of HIV, hepatitis B virus, and other bloodborne pathogens in health care settings: a review of risk factors and guidelines for prevention. World Health Organization. , 1991, Bulletin of the World Health Organization.

[24]  Kingsley,et al.  Sexual transmission efficiency of hepatitis B virus and human immunodeficiency virus among homosexual men. , 1990, Critical care nurse.

[25]  H. Daniels,et al.  Foscarnet therapy in chronic hepatitis B virus e antigen carriers , 1989, Journal of medical virology.

[26]  J. Hoofnagle,et al.  Chronic type B hepatitis and the “healthy” Hbsag carrier state , 1987, Hepatology.

[27]  M. Colombo,et al.  A multicenter, prospective study of posttransfusion hepatitis in milan , 1987, Hepatology.

[28]  M. Alter,et al.  Hepatitis B virus transmission between heterosexuals. , 1986, JAMA.

[29]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[30]  T R Bender,et al.  Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. , 1985, The Journal of infectious diseases.

[31]  B. Öberg.  Antiviral effects of phosphonoformate (PFA, foscarnet sodium). , 1982 .

[32]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.

[33]  H. Balfour,et al.  Transmission of hepatitis B virus in clinical laboratory areas. , 1979, Journal of Infectious Diseases.

[34]  C E Stevens,et al.  The e antigen and vertical transmission of hepatitis B surface antigen. , 1977, American journal of epidemiology.

[35]  M. Hatch,et al.  Epidemic viral hepatitis, type B, in hospital personnel. , 1974, The American journal of medicine.